The oncological outcomes of low ligation (LL) compared to high ligation (HL) of the inferior mesenteric artery (IMA) during low-anterior rectal resection (LAR) with total mesorectal excision are still debated. The aim of this study is to report the 5 year oncologic outcomes of patients undergoing laparoscopic LAR with either HL vs. LL of the IMA MATERIALS AND METHODS: Between June 2014 and December 2016, patients who underwent elective laparoscopic LAR + TME in 6 Italian non-academic hospitals were randomized to HL or LL of IMA after meeting the inclusion criteria (HighLow trial; ClinicalTrials.gov Identifier NCT02153801). We analyzed the rate of local recurrence, distant metastasis, overall survival, disease-specific survival, and disease-free survival at 5 years of patients previously enrolled.

5 year oncological outcomes of the HIGHLOW randomized clinical trial / Mari, Giulio; Santambrogio, Gaia; Crippa, Jacopo; Cirocchi, Roberto; Origi, Matteo; Achilli, Pietro; Ferrari, Giovanni; Megna, Stefano; Desio, Matteo; Cocozza, Eugenio; Maggioni, Dario; Montroni, Isacco; Spinelli, Antonino; Zuliani, Walter; Costanzi, Andrea; Crestale, Sara; Petri, Roberto; Bicelli, Noemi; Pedrazzani, Corrado; Boccolini, Andrea; Taffurelli, Giovanni; Fingerhut, Abe. - In: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY. - ISSN 0748-7983. - 2023/49:3(2023), pp. 641-646. [10.1016/j.ejso.2022.10.017]

5 year oncological outcomes of the HIGHLOW randomized clinical trial

Pedrazzani, Corrado;
2023-01-01

Abstract

The oncological outcomes of low ligation (LL) compared to high ligation (HL) of the inferior mesenteric artery (IMA) during low-anterior rectal resection (LAR) with total mesorectal excision are still debated. The aim of this study is to report the 5 year oncologic outcomes of patients undergoing laparoscopic LAR with either HL vs. LL of the IMA MATERIALS AND METHODS: Between June 2014 and December 2016, patients who underwent elective laparoscopic LAR + TME in 6 Italian non-academic hospitals were randomized to HL or LL of IMA after meeting the inclusion criteria (HighLow trial; ClinicalTrials.gov Identifier NCT02153801). We analyzed the rate of local recurrence, distant metastasis, overall survival, disease-specific survival, and disease-free survival at 5 years of patients previously enrolled.
2023
3
Mari, Giulio; Santambrogio, Gaia; Crippa, Jacopo; Cirocchi, Roberto; Origi, Matteo; Achilli, Pietro; Ferrari, Giovanni; Megna, Stefano; Desio, Matteo;...espandi
5 year oncological outcomes of the HIGHLOW randomized clinical trial / Mari, Giulio; Santambrogio, Gaia; Crippa, Jacopo; Cirocchi, Roberto; Origi, Matteo; Achilli, Pietro; Ferrari, Giovanni; Megna, Stefano; Desio, Matteo; Cocozza, Eugenio; Maggioni, Dario; Montroni, Isacco; Spinelli, Antonino; Zuliani, Walter; Costanzi, Andrea; Crestale, Sara; Petri, Roberto; Bicelli, Noemi; Pedrazzani, Corrado; Boccolini, Andrea; Taffurelli, Giovanni; Fingerhut, Abe. - In: EUROPEAN JOURNAL OF SURGICAL ONCOLOGY. - ISSN 0748-7983. - 2023/49:3(2023), pp. 641-646. [10.1016/j.ejso.2022.10.017]
File in questo prodotto:
File Dimensione Formato  
PIIS0748798322007090.pdf

Solo gestori archivio

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 456.09 kB
Formato Adobe PDF
456.09 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/480257
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 13
  • OpenAlex 14
social impact